Epidarex Capital Raises $145M to Boost UK & US Life Sciences

Epidarex Capital, a transatlantic venture firm, has announced a first close of over $145 million for its new fund, Epidarex Capital IV, LP. The fund aims to fuel early-stage investments in life sciences startups across the UK and the US, focusing on groundbreaking research to develop therapeutics and medical devices. With the potential to invest in up to 15 companies, this initiative could significantly impact the life sciences industry by fostering innovation and addressing unmet medical needs. 

Epidarex Capital, backed by esteemed investors like the British Business Bank and the Scottish National Investment Bank, is dedicated to bridging the early-stage funding gap often faced by life sciences ventures. With its focus on areas such as oncology, cardiometabolic diseases, autoimmunity, and neurology, the firm’s portfolio underscores its commitment to translating pioneering science into viable healthcare solutions. This fund launch comes at a crucial time as large pharmaceutical companies increasingly search externally for innovation, and academic labs continue producing world-class science. Epidarex’s previous successes, including Apellis Pharmaceuticals and Kynos Therapeutics, highlight the firm’s strategy of transforming academic research into thriving businesses.

Epidarex Capital’s latest fund represents a significant step forward in fostering life sciences innovation on both sides of the Atlantic. By investing in early-stage companies, Epidarex is poised to drive the development of novel therapies and medical devices. This proactive approach contrasts with other investment firms like Gimv, which have shifted focus away from life sciences. Overall, Epidarex’s efforts signal a promising future for the sector and underscore the importance of nurturing breakthrough scientific discoveries.